A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cuta- neous leishmaniasis by Leishmania guyanensis * Estudo clínico randomizado comparando antimoniato de meglumina, pentami- dina e anfotericina B para o tratamento da leishmaniose cutân

@inproceedings{Neves2011ARC,
  title={A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cuta- neous leishmaniasis by Leishmania guyanensis * Estudo cl{\'i}nico randomizado comparando antimoniato de meglumina, pentami- dina e anfotericina B para o tratamento da leishmaniose cut{\^a}n},
  author={Leandro Ourives Neves and Anette Chrusciak Talhari and Ellen Priscilla and Nunes Gadelha and Roberto Moreira da Silva J{\'u}nior and Jorge Augusto and Oliveira Guerra and Luiz C L Ferreira},
  year={2011}
}
Fundamentals: American tegumentary leishmaniasis (ATL) treatment remains a challenge, since most available drugs are injectable and only a small number of comparative, randomized clinical trials have been performed to support their use. Moreover, treatment outcome may depend on the causative species of Leishmania. O BJECTIVES: To evaluate and compare the efficacy and tolerability of meglumine antimoniate, pentamidine isethionate, and amphotericin B in the treatment of ATL caused by Leishmania… CONTINUE READING

Topics from this paper.